Syneos Health Leaders Recognized by Healthcare Businesswomen’s Association
May 13, 2024 08:00 ET
|
Syneos Health, Inc.
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced that Katie Mahony, Director, Value &...
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024 08:00 ET
|
Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
Humacyte to Participate at Upcoming Investor Conferences in May
May 13, 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
May 13, 2024 07:15 ET
|
Milestone Pharmaceuticals Inc.
– NDA for etripamil in PSVT resubmitted in 1Q 2024– Cash resources as of March 31, 2024 expected to fund operations into 2026– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR...
ORLADEYO® (berotralstat) Approved in Mexico
May 13, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks...
Fortrea Reports First Quarter 2024 Results
May 13, 2024 06:30 ET
|
Fortrea Holdings Inc
For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings...
Humacyte First Quarter 2024 Financial Results and Business Update
May 10, 2024 07:00 ET
|
Humacyte, Inc
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43...
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
May 10, 2024 07:00 ET
|
ProKidney
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a...
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
May 09, 2024 16:51 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024 10:00 ET
|
Science 37, Inc.
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.